

# M T Nurmohamed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5398538/publications.pdf>

Version: 2024-02-01

176  
papers

9,443  
citations

50170

46  
h-index

40881

93  
g-index

179  
all docs

179  
docs citations

179  
times ranked

9667  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 17-28.	0.5	918
2	Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1460.	3.8	656
3	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 921-926.	0.5	492
4	2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1251-1260.	0.5	450
5	Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 585-592.	1.6	325
6	Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRA% Investigation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1395-1400.	0.5	319
7	Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. <i>Arthritis and Rheumatism</i> , 2009, 61, 1571-1579.	6.7	318
8	Cardiovascular comorbidity in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 693-704.	3.5	260
9	Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. <i>Rheumatology</i> , 2014, 53, 2143-2154.	0.9	239
10	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 211-216.	0.5	224
11	Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. <i>Arthritis Research and Therapy</i> , 2006, 8, R151.	1.6	214
12	Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1914-1915.	0.5	196
13	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.5	179
14	Key findings towards optimising adalimumab treatment: the concentrationâ€“effect curve. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 513-518.	0.5	169
15	Interferon type I signature may predict non response upon rituximab in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2012, 14, R95.	1.6	157
16	Rheumatoid arthritis and metabolic syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 691-696.	3.5	154
17	Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. <i>Rheumatology International</i> , 2017, 37, 487-493.	1.5	146
18	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e778-e788.	2.2	130

#	ARTICLE	IF	CITATIONS
19	Is atherosclerosis an autoimmune disease?. BMC Medicine, 2014, 12, 47.	2.3	122
20	Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Annals of the Rheumatic Diseases, 2012, 71, 88-91.	0.5	121
21	Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatology, The, 2021, 3, e58-e70.	2.2	121
22	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. PLoS ONE, 2015, 10, e0122271.	1.1	120
23	Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Reviews Rheumatology, 2012, 8, 224-234.	3.5	118
24	Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor $\alpha$ blockade. Annals of the Rheumatic Diseases, 2009, 68, 362-366.	0.5	101
25	Signs of Accelerated Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 161-166.	1.0	99
26	Cardiovascular disease in inflammatory rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 851-869.	1.4	95
27	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Annals of the Rheumatic Diseases, 2012, 71, 1950-1954.	0.5	91
28	Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Annals of the Rheumatic Diseases, 2015, 74, 361-368.	0.5	81
29	Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart, 2016, 102, 790-795.	1.2	79
30	Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatology, The, 2021, 3, e241-e243.	2.2	72
31	Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Annals of the Rheumatic Diseases, 2014, 73, 2178-2182.	0.5	70
32	Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. Journal of Immunological Methods, 2015, 418, 29-38.	0.6	70
33	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis and Rheumatism, 2012, 64, 3850-3855.	6.7	68
34	HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Annals of the Rheumatic Diseases, 2013, 72, 560-565.	0.5	68
35	Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Annals of the Rheumatic Diseases, 2014, 73, 954-957.	0.5	68
36	Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Annals of the Rheumatic Diseases, 2015, 74, 396-401.	0.5	66

#	ARTICLE	IF	CITATIONS
37	The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 38-41.	0.6	60
38	IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients. <i>Journal of Clinical Immunology</i> , 2012, 32, 1000-1006.	2.0	57
39	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	3.5	57
40	Adalimumab Significantly Reduces the Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2014, 41, 1843-1848.	1.0	56
41	Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 404-412.	3.7	56
42	Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e542-e545.	2.2	54
43	Cardiovascular and Cerebrovascular Diseases in Ankylosing Spondylitis: Current Insights. <i>Current Rheumatology Reports</i> , 2012, 14, 415-421.	2.1	53
44	Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1825-1829.	0.5	51
45	The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. <i>International Journal of Clinical Practice</i> , 2010, 64, 1440-1443.	0.8	49
46	Management and evaluation of extra-articular manifestations in spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 413-422.	1.2	49
47	Cardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus and osteoarthritis: a cross-sectional study in primary care. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 150.	0.8	48
48	Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e87965.	1.1	47
49	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 14.	0.8	44
50	Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab – The GO-EASY Study. <i>Journal of Rheumatology</i> , 2019, 46, 153-159.	1.0	43
51	The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis. <i>Current Pharmaceutical Design</i> , 2012, 18, 1502-1511.	0.9	42
52	Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1510-1516.	0.5	41
53	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
54	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology</i> , The, 2020, 2, e583-e585.	2.2	40

#	ARTICLE	IF	CITATIONS
55	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 176.	0.8	36
56	Comorbidities in Patients with Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 523-538.	0.8	33
57	Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2217-2219.	0.5	33
58	Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000080-e000080.	1.8	33
59	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 610-616.	0.5	33
60	Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review. <i>Nutrients</i> , 2019, 11, 2955.	1.7	33
61	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e417-e429.	2.2	33
62	Diastolic left ventricular dysfunction in ankylosing spondylitis – A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 14-19.	1.6	32
63	Increased risk for chronic comorbid disorders in patients with inflammatory arthritis: a population based study. <i>BMC Family Practice</i> , 2013, 14, 199.	2.9	31
64	Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti- $\alpha$ adalimumab in patients with inflammatory diseases. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2474-2484.	1.1	31
65	Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2016, 18, 115.	1.6	30
66	Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 87-94.	0.6	30
67	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , 2018, 41, 473-488.	1.4	30
68	Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2012, 14, R52.	1.6	29
69	Association of Somatic Comorbidities and Comorbid Depression With Mortality in Patients With Rheumatoid Arthritis: A 14-Year Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1055-1060.	1.5	27
70	Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1848-1851.	0.5	26
71	Noncanonical NF- $\kappa$ B signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction. <i>Atherosclerosis</i> , 2018, 270, 33-41.	0.4	26
72	High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study. <i>Journal of Rheumatology</i> , 2013, 40, 825-830.	1.0	24

#	ARTICLE	IF	CITATIONS
73	Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STATins to Prevent Rheumatoid Arthritis (STAPRA) trial. <i>RMD Open</i> , 2021, 7, e001591.	1.8	24
74	Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1737-1745.	2.9	23
75	Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1675-1683.	6.7	22
76	Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 80.	0.8	22
77	Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 758-764.	1.0	22
78	Dyslipidaemia in patients with seropositive arthralgia predicts the development of arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1915-1916.	0.5	20
79	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017, 56, 1586-1596.	0.9	20
80	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925.	1.4	20
81	An unfavorable body composition is common in early arthritis patients: A case control study. <i>PLoS ONE</i> , 2018, 13, e0193377.	1.1	19
82	A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15105.	0.5	19
83	Different Type of Carotid Arterial Wall Remodeling in Rheumatoid Arthritis Compared with Healthy Subjects: A Case-Control Study. <i>Journal of Rheumatology</i> , 2012, 39, 2261-2266.	1.0	18
84	Fat Mass Lowers the Response to Tumor Necrosis Factor- $\beta$ Blockers in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2017, 44, 1355-1361.	1.0	18
85	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.5	18
86	Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. <i>Journal of Clinical Medicine</i> , 2022, 11, 2704.	1.0	18
87	Reduction of Inflammation Drives Lipid Changes in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2015, 42, 1842-1845.	1.0	17
88	The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2021, 41, 319-328.	1.5	17
89	Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step?. <i>Arthritis Research and Therapy</i> , 2013, 15, 111.	1.6	16
90	Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review. <i>Current Medicinal Chemistry</i> , 2015, 22, 1892-1902.	1.2	16

#	ARTICLE	IF	CITATIONS
91	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. <i>RMD Open</i> , 2016, 2, e000228.	1.8	15
92	The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1362-1368.	1.0	15
93	Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 345-352.	0.6	15
94	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. <i>Rheumatology</i> , 2020, 59, 1253-1261.	0.9	15
95	Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 806-815.	2.9	15
96	Biologics, cardiovascular effects and cancer. <i>BMC Medicine</i> , 2014, 12, 48.	2.3	14
97	Objective Evaluation of Physical Functioning after Tumor Necrosis Factor Inhibitory Therapy in Patients with Ankylosing Spondylitis: A Selection of 3 Feasible Performance-based Tests. <i>Journal of Rheumatology</i> , 2015, 42, 623-629.	1.0	14
98	The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1615-1622.	0.9	14
99	Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. <i>PLoS ONE</i> , 2018, 13, e0205125.	1.1	14
100	Neutrophil activation identifies patients with active polyarticular gout. <i>Arthritis Research and Therapy</i> , 2020, 22, 148.	1.6	14
101	Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. <i>Clinical Rheumatology</i> , 2012, 31, 1677-1682.	1.0	13
102	Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT. <i>PLoS ONE</i> , 2017, 12, e0181847.	1.1	13
103	Editorial: Comorbidity Burden in Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 197.	1.2	13
104	COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2022, 4, e310-e313.	2.2	12
105	Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylolation revisited. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 331-334.	0.4	11
106	Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 266-270.	0.6	11
107	Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. <i>RMD Open</i> , 2022, 8, e002035.	1.8	11
108	Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 331-334.	0.6	10

#	ARTICLE	IF	CITATIONS
109	The Relationship Between Cardiac Conduction Times, Cardiovascular Risk Factors, and Inflammation in Patients with Early Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 580-586.	1.0	10
110	Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 122-126.	0.6	10
111	Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period. <i>Clinical Rheumatology</i> , 2020, 39, 1521-1529.	1.0	10
112	The Effect of Anti-TNF Therapy on Cardiac Function in Rheumatoid Arthritis: An Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3145.	1.0	10
113	Cardiovascular risk in persons at risk of developing rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0237072.	1.1	10
114	The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patientsâ€”The CARDAS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5069.	1.0	10
115	Coexistence of hypothyroidism with inflammatory arthritis is associated with cardiovascular disease in women. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1216-1218.	0.5	9
116	Brief Report: The Role of Rare Proteinâ€Coding Variants in Antiâ€Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 735-741.	2.9	8
117	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. <i>Arthritis Care and Research</i> , 2017, 69, 989-996.	1.5	8
118	Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence. <i>PLoS ONE</i> , 2019, 14, e0221290.	1.1	8
119	The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, 1703-1708.	0.9	8
120	Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 129-136.	0.6	8
121	Hypothyroidism in Rheumatoid Arthritis â€” To Screen or Not to Screen?. <i>Journal of Rheumatology</i> , 2012, 39, 885-886.	1.0	7
122	Effective Treatment for Rapid Improvement of Both Disease Activity and Selfâ€Reported Physical Activity in Early Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 280-284.	1.5	7
123	Cardiovascular safety of celecoxib, naproxen and ibuprofen. <i>Nature Reviews Rheumatology</i> , 2017, 13, 136-138.	3.5	7
124	Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance. <i>Clinical Rheumatology</i> , 2018, 37, 2151-2159.	1.0	7
125	Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation. <i>Rheumatology International</i> , 2022, 42, 683-688.	1.5	7
126	Editorial: Treat to Target in Rheumatoid Arthritis: Good for the Joints as Well as the Heart?. <i>Arthritis and Rheumatology</i> , 2015, 67, 1412-1415.	2.9	6



#	ARTICLE	IF	CITATIONS
127	Immune-mediated inflammatory disease patientsâ€™ preferences in adverse drug reaction information regarding biologics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1049-1054.	1.0	6
128	Cardiorespiratory fitness and physical activity in people who have rheumatoid arthritis at an increased risk of cardiovascular disease: a cross-sectional study. <i>Rheumatology International</i> , 2021, 41, 2177-2183.	1.5	6
129	Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab. <i>BMJ Case Reports</i> , 2021, 14, e237549.	0.2	5
130	Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 597-599.	0.5	5
131	Comparing inflammatory cell density in the myocardium and coronary arteries in rheumatoid arthritis patients versus controls with myocardial infarction: A post-mortem caseâ€“control study. <i>International Journal of Cardiology</i> , 2016, 209, 74-76.	0.8	4
132	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
133	Response to: â€œInfluence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patientsâ€“by Fornaro et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e105-e105.	0.5	4
134	Correspondence on â€œAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registryâ€“by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221146.	0.5	4
135	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. <i>Osteoporosis International</i> , 2021, 32, 1441-1449.	1.3	4
136	A1.77â€“Interferon regulatory factor 5 (IRF5) gene variant RS2004640 is associated with carotid intima media thickness in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A34.1-A34.	0.5	3
137	The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis. <i>Biologics: Targets and Therapy</i> , 2018, Volume 12, 143-149.	3.0	3
138	Multicentric reticulohistiocytosis: a case report. <i>BMC Research Notes</i> , 2018, 11, 647.	0.6	3
139	E064â€“The relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme. <i>Rheumatology</i> , 2019, 58, .	0.9	3
140	Are Health Care Professionalsâ€™ Implicit and Explicit Attitudes Toward Conventional Diseaseâ€“Modifying Antirheumatic Drugs Associated With Those of Their Patients?. <i>Arthritis Care and Research</i> , 2021, 73, 364-373.	1.5	3
141	Elevated Fab glycosylation of anti-hinge antibodies. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	0.6	3
142	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. <i>RMD Open</i> , 2017, 3, e000502.	1.8	3
143	Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. <i>RMD Open</i> , 2022, 8, e001712.	1.8	3
144	Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1196-1197.	0.5	3

#	ARTICLE	IF	CITATIONS
145	Gastrointestinal Events in Rheumatoid Arthritis: Time for the Lower Gastrointestinal Tract!. Journal of Rheumatology, 2012, 39, 1317-1319.	1.0	2
146	OP0002â€¦Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 52.2-52.	0.5	2
147	Cardiovascular Disease Reduction in Rheumatoid Arthritis by Statins: The Final Evidence?. Journal of Rheumatology, 2016, 43, 1950-1952.	1.0	2
148	245â€¦Remission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors. Rheumatology, 2019, 58, .	0.9	2
149	Stakeholdersâ€™ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. Expert Opinion on Drug Safety, 2020, 19, 1521-1528.	1.0	2
150	Accuracy of an algorithm to identify rheumatoid arthritis in the Longitudinal Ageing Study Amsterdam population: a validation study. Scandinavian Journal of Rheumatology, 2021, 50, 290-294.	0.6	2
151	POS0669â€¦HYPOGLYCAEMIA FOLLOWING JAK INHIBITOR TREATMENT IN DIABETES MELLITUS PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 578-579.	0.5	2
152	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. Journal of Rheumatology, 2021, 48, 1388-1394.	1.0	2
153	NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 243-249.	0.6	2
154	Cardiovascular disease management in RA. Arthritis and Rheumatism, 2013, , n/a-n/a.	6.7	1
155	Response to: â€˜Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS studyâ€™ by Marotte <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e82-e82.	0.5	1
156	Favorable effects on the hemostatic system in ankylosing spondylitis patients treated with golimumab. Joint Bone Spine, 2021, 88, 105102.	0.8	1
157	POS0524â€¦CARDIOVASCULAR DISEASE RISK IN INFLAMMATORY ARTHRITIS PATIENTS STILL SUBSTANTIALLY ELEVATED IN 2020. Annals of the Rheumatic Diseases, 2021, 80, 495.2-496.	0.5	1
158	Managing Cardiovascular Risk in Rheumatoid Patients. American Journal of Cardiology, 2012, 110, 763.	0.7	0
159	A5.30â€¦Systemic Inflammation and B-Cells in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A41.2-A41.	0.5	0
160	Response to: â€˜The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritisâ€™ by GonzÃ¡lez-Gayet al. Annals of the Rheumatic Diseases, 2014, 73, e28-e28.	0.5	0
161	OP0013â€¦Effective Treatment Rapidly Improves both Disease Activity and Physical Activity in Early Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2015, 74, 69.1-69.	0.5	0
162	AB0287â€¦High Levels of 25(OH)D Are Associated with Lower Disease Activity in Patients with Newly Diagnosed Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2015, 74, 989.1-989.	0.5	0

#	ARTICLE	IF	CITATIONS
163	Cardiovascular Disease-related Hospital Admissions of Patients with Inflammatory Arthritis. Journal of Rheumatology, 2015, 42, 188-192.	1.0	0
164	OP0262â€¦Similar Clinical and Radiological Outcome in The Cobra and Cobra-Light Treatment Group 4 Years after Initiation of The Cobra-Light Trial. Annals of the Rheumatic Diseases, 2016, 75, 157.2-157.	0.5	0
165	THU0104â€¦Limited Safety Signals, but No Advantage of Cobra-Light over Cobra Combination Therapy 4 Years after Initiation of The Cobra-Light Trial in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 217.1-217.	0.5	0
166	AB0265â€¦Non-Canonical NF-Î²B Signaling in Microvessels of Atherosclerotic Lesions in Coronary Arteries Is Associated with Inflammatory Cell Infiltration and Myocardial Infarction. Annals of the Rheumatic Diseases, 2016, 75, 990.2-990.	0.5	0
167	THU0064â€¦Short and Sustained Periods of ACR/EULAR Remission Predict Good Functional Outcome, but Not Stable Radiographic Outcome in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 201.1-201.	0.5	0
168	THU0062â€¦Prognosis of Early Rheumatoid Arthritis Patients with Erosive Disease at Baseline. Annals of the Rheumatic Diseases, 2016, 75, 200.2-200.	0.5	0
169	SP0127â€¦Tapering biologics induces a prothrombotic state in rheumatoid arthritis?. , 2017, , .		0
170	Can personalized use of NSAIDs be a reality in the clinic?. Nature Reviews Rheumatology, 2019, 15, 387-388.	3.5	0
171	AB0733â€¦AN EYE FOR THE HEART: ARE RETINAL VASCULAR PARAMETERS ASSOCIATED WITH CARDIOVASCULAR DISEASE IN ANKYLOSING SPONDYLITIS?. , 2019, , .		0
172	Reply. Arthritis and Rheumatology, 2021, 73, 2352-2353.	2.9	0
173	Patientsâ€™ perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opinion on Drug Safety, 2021, 20, 1-8.	1.0	0
174	SP0087â€¦How to deal with cardiovascular risk factors for physical activity and implement the pa recommendations in the rheumatologic practice?. , 2018, , .		0
175	SAT0143â€¦The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy. , 2018, , .		0
176	Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial. Scandinavian Journal of Rheumatology, 2022, , 1-5.	0.6	0